C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
C4 Therapeutics insider filing: The reporting person, Kendra Adams (CFO), acquired 6,250 shares of common stock on 09/18/2025 upon vesting of previously granted restricted stock units (RSUs). The shares were issued at no cash price upon vesting and increased her beneficial holdings to 165,117 shares. In connection with the vesting, the issuer withheld 2,775 shares to satisfy tax withholding obligations, which reduced the net shares delivered and left 162,342 shares listed after the withholding entry on the Form 4.
C4 Therapeutics (NASDAQ: CCCC) Q2 2025 10-Q highlights
- Revenue: $6.5 m from collaborations, down 46 % YoY (Q2 24: $12.0 m) as Biogen–related income rolled off.
- Expenses: R&D $26.2 m (+10 % YoY); G&A $8.8 m (-10 % YoY). Total op-ex $35.0 m (+4 %).
- Losses: Operating loss widened to $28.5 m; net loss $26.0 m (-$0.37 pps) versus $17.7 m (-$0.26 pps) a year ago. 1H 25 net loss $52.3 m.
- Cash runway: Cash, cash equivalents & marketable securities were $223 m at 6-30-25 (vs. $267 m at 12-31-24); management projects ≥12-month runway.
- Balance sheet: Deferred revenue $43.8 m, reflecting future work under Roche, MKDG, Merck and Betta deals; no debt.
- Collaboration momentum: Earned $1 m discovery milestone (MKDG) and two $2 m lead-series milestones (Roche). Q2 revenue mix: MKDG 53 %, Roche 30 %, Merck 16 %, Betta 1 %.
- Share count: 71.2 m outstanding (7-29-25) after equity comp and ESPP; authorized shares doubled to 300 m.
- Guidance & risk: Company remains clinical-stage with no product sales; relies on external funding and partner milestones; accumulated deficit $686 m.
The filing affirms strategic focus on protein-degrader oncology programs (e.g., CFT8919, DACs) while controlling G&A. Near-term catalysts hinge on progress within partnered pipelines and internal Phase 1 assets.
C4 Therapeutics Director Utpal Koppikar received a stock option grant on June 18, 2025, as reported in this Form 4 filing. The derivative securities transaction involved:
- Grant of 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting
The options are subject to continued service as a Board member through the vesting date. This grant appears to be part of the company's director compensation program. The transaction was reported by attorney-in-fact Jolie M. Siegel on June 20, 2025.
C4 Therapeutics Director Owen Hughes received a stock option grant on June 18, 2025, representing a significant insider transaction. The derivative securities transaction details include:
- Granted 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting schedule: Full vesting upon earlier of June 18, 2026 or next annual stockholder meeting
This Form 4 filing indicates standard board compensation practices through equity grants. The vesting conditions require continued service as a board member, aligning the director's interests with long-term shareholder value. The transaction was executed under direct ownership, with attorney Jolie M. Siegel signing as the authorized representative.